Panel Discussion: Shaping the Future of Combination Radioligand Therapy: Preclinical Perspectives
- Balancing toxicity and efficacy: minimizing radiopharmaceutical dose while enhancing tumor kill
- Timing combination therapies: strategies for preclinical-to-clinical translation
- Selecting patients using biomarkers to match optimal RLT combinations with tumor and TME characteristics